Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGT | O15294 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17406962 | 1.00 | OGT (0.66) | OGTLMNAPKMPOLBF2 | |
| SCHEMBL18965303 | 1.00 | OGT (0.66) | OGTLMNAPKMPOLBF2 | |
| SCHEMBL17406929 | 0.87 | OGT (0.50) | OGTLMNAPKMPOLBMEN1 | |
| SCHEMBL17406934 | 0.86 | ALDH1A1 (0.58) | OGTLMNAPKMPOLBMEN1 | |
| SCHEMBL4544734 | 0.86 | OGT (0.49) | OGTLMNAPKMPOLBMEN1 | |
| SCHEMBL2633965 | 0.85 | OGT (0.51) | OGTLMNAPKMPOLBMEN1 | |
| SCHEMBL17406949 | 0.85 | ALDH1A1 (0.62) | OGTLMNAPKMPOLBF2 | |
| SCHEMBL17406948 | 0.85 | OGT (0.51) | OGTLMNAPKMPOLBMEN1 | |
| SCHEMBL4544731 | 0.84 | OGT (0.66) | OGTLMNAPKMPOLBF10 | |
| SCHEMBL18960139 | 0.83 | F2 (0.47) | OGTLMNAF2F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-15 | — | — | US | disclosed |
| US-8957075-B2 | O-GlcNAc transferase inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957075-B2 | O-GlcNAc transferase inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-02-17 | — | — | US | disclosed |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2010141074-A2 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | OGA, OGT, CSGALNACT1 | OGT 2/4885LMNA 4673/4885PKM 3290/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | OGT 815/4885LMNA 2020/4885PKM 4523/4885 |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | OGA, OGT, UGGT1 | OGT 2/4885LMNA 4381/4885PKM 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.